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Abstract
Background: The actions of adipocytokines may be a connective factor between obesity and polycystic ovary syndrome (PCOS). It is
suggested that irisin, as recently described cytokine secreted by skeletal muscles and glucose-dependent insulinotropic polypeptide
(GIP) as an incretin hormone that induces cytokine expression, may play key roles in favoring obesity in these women.
Objectives: We aimed to evaluate the association between body mass index (BMI) and serum concentration of irisin/GIP in women
with and without PCOS in the linear and non-linear model.
Methods: This cross-sectional study was conducted among 159 PCOS and 82 healthy eumenorrheic non-hirsute women aged 20
- 50 years. The fractional-polynomial model was used to develop a model of continuous risk factors, which evaluates non-linear
associations between irisin/GIP and BMI among women with and without PCOS.
Results: Women with PCOS were significantly younger (28.2 ± 5.8 vs. 33.0 ± 7.8 years, P < 0.001) and had a greater BMI (26.6 ± 5.2
vs. 25.2 ± 4.8 kg/m2, P = 0.04) than the healthy counterparts. There were no significant linear and non-linear associations between
serum concentration of irisin/GIP and BMI in both groups. The analysis of pair-wise age and BMI matching of women with PCOS and
controls confirmed these findings.
Conclusions: This study showed that irisin and GIP have no association with BMI in women with or without PCOS. This finding
could help to better understand the underlying pathophysiological status of PCOS, insulin resistance, and obesity-related disorders.
Further large cohort studies are needed to confirm these findings.
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1. Background
Polycystic ovary syndrome (PCOS) is the most common
endocrinopathy among women of reproductive age (1).
The syndrome is highly associated with reproductive and
metabolic disturbance (2, 3). Women with PCOS present
with greater risk for hyperandrogenism, hyperinsuline-
mia, impaired glucose tolerance, and type 2 diabetes mel-
litus (T2DM) (4, 5). While the underlying pathogenesis of
PCOS is still unclear, the role of insulin resistance (IR) and
impaired adipocytokines actions secreted by adipose tis-
sue have recently been explored (6-8).
Adipose tissue is identified as an active endocrine or-
gan that could regulate insulin sensitivity by adipocy-
tokines secretion via hormonal signals (9) and regulation
of thermogenesis (10).
Irisin, as a novel adipokine/myokine hormone, mainly
produced from myokine after physical exercise, could pro-
mote adipose tissue energy expenditure (11). Recent stud-
ies indicated that irisin is associated with obesity, T2DM,
and gestational T2DM (12-14). Moreover, it is suggested
that irisin metabolism is abnormal in patients with PCOS,
which may result in susceptibility to PCOS development
(15, 16).
In addition, studies have shown that glucose-
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dependent insulinotropic peptide (GIP), as the stimulator
of insulin release after nutrients intake, is impaired in
many patients with IR and obesity (16-19). This peptide
could regulate the deposition of some lipids in the muscle
or liver and insulin-mediated uptake of glucose into white
adipose tissues (20).
However, there have been some debates about the role
of obesity in the association of irisin/GIP and PCOS. The
over-expression or their reduced productions have been re-
ported in obese patients with PCOS (17, 21). Seemingly, these
cytokines may be a connective factor between obesity, IR,
and PCOS.
2. Objectives
This study aimed to investigate the linear and non-
linear association between body mass index (BMI) and
serum concentration of irisin/GIP in women with and with-
out PCOS.
3. Methods
The study proposal was approved by the Ethics Com-
mittee of the Research Institute for Endocrine Sciences,
Shahid Beheshti University of Medical Sciences, Iran. A
written informed consent was obtained from all women
who willingly accepted to participate in this study.
3.1. Study Population
This cross-sectional case-control study was conducted
among 159 women aged 20 - 50 years who were known
cases of PCOS referred from outpatient endocrinology
clinic in Tehran from March 2015 to March 2018. Also, 82
healthy eumenorrheic non-hirsute volunteer women aged
20 - 50 years were recruited as healthy controls. Exclusion
criteria were history of endocrine disorders, including thy-
roid diseases, hyperprolactinemia, and known hyperan-
drogenic disorders, as well as any medication that may in-
terfere with the normal function of the adipokines, includ-
ing anti-androgen and anti-lipid therapies, anti-diabetic
agents, glucocorticoids, and any hormones. Moreover,
menopausal or pregnant women and those with men-
strual irregularities or hyperandrogenism were excluded.
3.2. Clinical and Biochemical Measurements
The weight and height were measured with light cloth-
ing without shoes by standard devices to the nearest 0.1 kg
and 0.5 cm, respectively. The waist circumference (WC) was
measured at the superior border of the iliac crest to the
nearest 0.5 cm. The hip circumference (HC) was measured
at the levels of buttocks’ maximum extension to the near-
est 0.5 cm. BMI was computed as dividing weight in kilo-
grams by height in meters squared. The waist-to-hip ratio
(WHR) was computed as the WC divided by the HC. Blood
pressure (BP) was measured in the sitting position after a
15-min rest using a standard mercury sphygmomanome-
ter, which was calibrated by the Iranian Institute of Stan-
dards and Industrial Research.
For biochemical measurements, a blood sample was
taken after 12 to 14 h of overnight fasting between 07:00
and 09:00 a.m., and then plasma was separated in a re-
frigerated centrifuge at 3000 rpm for ten minutes, and
sera were stored at -80ºC until tested. Sex hormone bind-
ing globulin was evaluated by enzyme immunometric as-
say (Mercodia, Uppsala, Sweden). Androstenedione and
total testosterone (TT) were evaluated using enzyme im-
munoassay (Diagnostic Biochem Canada). All enzyme-
linked immunosorbent assay (ELISA) tests were performed
using the Sunrise ELISA reader (Tecan Co. Salzburg, Aus-
tria). All samples were analyzed when internal quality con-
trol met the acceptable criteria. The intra-assay and inter-
assay coefficients of variation (CV) for TT were 3.6% and
6.0%, for sex hormone-binding globulin 1.1% and 4.1%, and
for androstenedione 2.2% and 3.5%, respectively. The irisin
and GIP were measured using a sandwich ELISA method
(ZellBio GmbH, Germany). The sensitivity and intra-assay
CV of studied adipokines were 0.09 ng/ mL, 5.8%, and 6.7%
for irisin and 10 pg/ml, 6.9%, and 77.5% for GIP, respectively.
3.3. Definition of Terms
The PCOS was diagnosed based on the US National In-
stitutes of Health (NIH) criteria, including presence of the
two following criteria: chronic oligo-anovulation and hy-
perandrogenism (clinical or biological) after exclusion of
other related disorders (22).
Oligo-anovulation was defined menstruation interval
of more than 37 days or a history of less than eight
menstrual cycles in a year (23). The clinical hyperan-
drogenism included hirsutism (according to modified
Ferriman-Gallwey scale score less than 8), androgenic
alopecia, or acne vulgaris. Biochemical hyperandrogenism
was defined as elevated serum concentration of one or
more androgens based on the 95th percentile of healthy
women (24).
3.5. Statistical Analysis
The sample size was calculated by using a two-sided
two-sample equal-variance t-test with the following param-
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eters: significance level = alpha 5%; power = 82.9%; and
mean difference (standard deviation) = 25.0 (65.0).
All variables were presented as mean (standard devia-
tion) or median with inter-quartile range (IQ25-75) as ap-
propriated. T-test and the Mann-Whitney U test were used
to compare the basic characteristics of healthy and PCOS
groups. To detect the relationship between irisin/GIP and
BMI, scatter plot matrix was drawn. We explored a more
exact association by fitting a fractional polynomial (FP) re-
gression model, which is a flexible parametric approach
to model continuous risk factors and evaluates the poten-
tial non-linear associations more precisely (25). We also
prepared data for pair-wise (1:1) age-BMI matching. Spear-
man’s correlation coefficient was used to determine the
relationship between the variables. The software package
STATA (version 14; STATA Inc., College station, TX, USA) was
used to perform all statistical analysis; the significance
level was set at P < 0.05.
4. Results
The characteristics of the women in both groups are
shown in Table 1. The women with PCOS were significantly
younger (28.2 ± 5.8 vs. 33.0 ± 7.8 years, P < 0.001), had
a greater BMI (26.6 ± 5.2 vs. 25.2 ± 4.8 kg/m2, P = 0.04),
and higher values for WC (88.9 ± 13.2 vs. 83.4 ± 11.3 cm, P
= 0.001) and WHR (0.85 ± 0.08 vs. 0.82 ± 0.07, P = 0.002)
than the healthy women.
Figure 1 shows the scatter plot matrix of irisin and
GIP levels against BMI, indicating no association between
irisin/GIP and BMI in both PCOS cases and healthy controls.
After adjusting for age, the results of FP analysis showed
that there were no significant linear nor non-linear associ-
ations between serum concentration of irisin/GIP and BMI
in both groups.
In addition, the association of irisin/GIP and BMI in
pair-wise age and BMI matching of women with PCOS (n =
68) and controls (n = 68) showed that there were no asso-
ciations between irisin/GIP and BMI in both PCOS (r = 0.02,
P = 0.8 for irisin and r = -0.03, P = 0.9 for GIP) and healthy
groups (r = 0.08, P = 0.5 for irisin and r = 0.01, P = 0.9 for
GIP).
5. Discussion
Results of the study demonstrated that there was no as-
sociation between irisin/GIP and BMI independent of the
age in women with and without PCOS using both linear
and non-linear methods. In addition, no correlation was
found in pair-wise age and BMI matching comparison be-
tween irisin/GIP and BMI in both PCOS and healthy groups.
The underlying etiology of PCOS, as a heterogeneous
disorder, is complex and multifactorial. It is suggested
that adiposity and related metabolic alterations play an
important role in the pathogenesis of PCOS (6). Several
muscle-derived factors are responsible for the modulation
of insulin sensitivity. Irisin, as a muscle-derived brown adi-
pose differentiation factor, is identified as a cleaved and se-
creted product of the Fndc5 protein (26). Irisin could in-
duce the translocation of glucose transporter type 4 (GLUT-
4) to the plasma membrane and stimulate glucose uptake
in differentiated skeletal muscles (27). Higher serum irisin
concentration is related to a greater energy expenditure
and diet-induced IR improvement (28). However, emerg-
ing literature showed that in aggravated IR status such as
metabolic syndrome, pre-diabetes, and PCOS, irisin con-
centrations compensatory increase to promote the insulin
sensitivity (15, 29, 30) In this respect, obesity, as an impor-
tant IR risk factor, may have a major effect in relation to
irisin and PCOS status.
There are limited studies with controversial results as-
sessing the correlation between BMI and irisin in both
PCOS and non-PCOS women. While some studies reported
that serum concentration of irisin in PCOS was negatively
associated with BMI (15), some investigations showed the
positive correlation (21, 31) or even no association between
circulating irisin levels and BMI (32, 33). Wang et al. eval-
uated the serum irisin in 40 women with PCOS and 30 in-
fertile women without PCOS. They showed that serum con-
centration of irisin was negatively associated with BMI (R
= -0.762 , P = 0.000), and irisin level in obese PCOS pa-
tients was significantly lower than that in non-obese PCOS
patients (15). On the contrary, Bostanci et al. evaluated
35 PCOS patients and reported that serum irisin was pos-
itively associated with BMI in the overall population, but
not for PCOS group alone (32). However, in agreement with
our study, Abali et al. (33) and Timmons et al. (34) reported
that irisin levels had no correlation with BMI.
The discrepancies in the above-mentioned studies may
be related to various PCOS population characteristics such
as different age, BMI, physical activity, ethnicity, and phe-
notypes of PCOS, which may influence plasma irisin lev-
els (35-37). Moreover, some studies suggested that patho-
logical state of POCS may influence the irisin level. In this
respect, it is suggested that irisin level in cases with the
newly diagnosed and well-regulated impaired insulin sen-
sitivity tend to be increased to compensate for the IR (36,
37). In contrast, in a fully developed IR situation, physiolog-
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Table 1. The Anthropometric, Clinical, and Biochemical Features of the Groupsa
Characteristics PCOS (N =159) Healthy (N= 82) P-Value
Age (y) 28.20 (5.81) 33.02 (7.83) < 0.001
BMI (kg/m2) 26.60 (5.24) 25.16 (4.82) 0.04
WC (cm) 88.93 (13.20) 83.40 (11.27) 0.001
WHR 0.85 (0.08) 0.82 (0.07) 0.002
SBP (mmHg) 105.19 (17.09) 101.19 (9.30) 0.007
DBP (mmHg) 72.37 (13.55) 65.54 (8.03) < 0.001
TT (ng/mL) 0.47 (0.28 - 0.90) 0.49 (0.39 - 0.68) 0.8
SHBG (nmol/L) 43.4 (33.6 - 53.7) 93 (69.0 - 121.0) < 0.001
Androstenedione (ng/m L) 1.20 (0.80 - 2.10) 1.36 (1.0 - 1.81) 0.6
Irisin (ng/mL) 404.65 (150.13) 372.46 (115.21) 0.1
GIP (pg/mL) 3.74 (3.15 - 4.76) 3.56 (2.62 - 4.51) 0.7
Abbreviations: PCOS, polycystic ovary syndrome; BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; SBP, systolic blood pressure; DBP, diastolic
blood pressure; TT, Total testosterone; SHBG, Sex Hormone Binding Globulin; GIP, glucose-dependent insulinotropic polypeptide.
aValues are given as mean (standard deviation) or median (IQR25%-75%), as appropriate. P-value is calculated by two independent sample t-test or Mann-Whitney U test























10                                       20                                       30                                       40                                       50













Figure 1. Scatter plot matrix of (A) irisin and (B) glucose-dependent insulinotropic polypeptide levels against body mass index.
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ical irisin cannot maintain the balance of IR, and thus irisin
levels may be remained in normal or even lower than nor-
mal levels (35-37). This finding suggests the relationship
between this hormone and the disease process (35). Sup-
porting this hypothesis, a lower concentration of irisin in
the presence of complications of T2DM compared to newly
diagnosed and well-regulated T2DM has been shown (36,
37). Zhang et al. (2014) showed a significantly reduced
serum concentrations of irisin among patients with T2DM
with macro/peripheral vascular complications and cardio-
vascular diseases compared to patients without such com-
plications (36). Accordingly, based on the findings of these
studies, it is hypothesized that the positive correlation of
circulating irisin with obesity may be nullified by other fac-
tors in the pathological states of obesity.
However, studies of human gut derived incretins, in-
cluding GIP, have shown that these hormones play a role
in the regulation of the triglycerides and insulin mediated
uptake of glucose (30-33). There are limited studies inves-
tigating the association between GIP and BMI in PCOS sub-
jects. Pontikis et al. investigated the secretion of GIP be-
tween age matched obese and lean patients with PCOS af-
ter oral glucose tolerance tests (OGTT). In agreement with
our findings, the GIP values did not differ between the
groups. However, after OGTT test, obese PCOS patients
demonstrated lower GIP level in response to OGTT com-
pared to the controls. The authors argued that although
the serum concentrations of GIP in different states of obe-
sity were similar, its response to the oral glucose tolerance
test and IR may be attenuated. This paper suggested that
the activity of the entero-insular axis may be impaired in
PCOS patients (38). However, many factors have been asso-
ciated with GIP responses, including age and gender (38),
BMI (17, 39), inflammatory cytokines (40), and IR and met-
formin treatment, which may have an important effect on
the findings. Further well-designed studies with an appro-
priate sample size are warranted to explore these associa-
tions.
Measurement of relatively new laboratory markers
and analysis by both linear and non-linear statistical mod-
els could be considered as the strengths of this study. How-
ever, there are some limitations that need to be considered
when interpreting the results of this study. The clinical-
based nature of this study might present severe pheno-
types of PCOS women referred for treatment. Therefore, it
could not be representative of all phenotypes of PCOS. In
addition, the current study was conducted among women
who referred to a tertiary clinic in Tehran, and the findings
need to be interpreted in other ethnicities with caution.
Moreover, lack of adequate samples did not allow to
perform the subgroup analyses based on various pheno-
types of PCOS. In addition, we did not assess other adipos-
ity indices, IR, OGTT, as well as IR related factors, which
may help to clarify the findings. Furthermore, the cross-
sectional design of this study and lack of specific data
on irisin protein levels in muscles restricted finding the
causal relationships between the studied variables. Finally,
since irisin is a kind of myokine which is secreted by exer-
cise, the evaluation of irisin level without including the ex-
ercise information may confound the findings.
5.1. Conclusions
This study showed that irisin and GIP have no associa-
tion with BMI in women with or without PCOS. This find-
ing could help to better understand the underlying patho-
physiological status of PCOS, IR, and obesity-related disor-
ders. Further large cohort studies are needed to confirm
these results.
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